The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Rheumatoid Arthritis: A Brief Overview of the Treatment
Open accessAbstract
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics, and environmental exposure (cigarette smoking, air pollutants, and occupational). Many complications can follow, such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis, and Felty syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pain and stop/slow further damage. Here, we present a brief summary of various past and present treatment modalities to address the complications associated with RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Smolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.1 · Cited by 2,445
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S., Schoels, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,465
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268
Alamanos, Y., Voulgari, P. V., & Drosos, A. A. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.08.006 · Cited by 782
Innate Immunity and the Failing Heart: The Cytokine Hypothesis Revisited
Mann, D. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.302317 · Cited by 689
2016 update of the EULAR recommendations for the management of early arthritis
Combe, B., Landewe, R., Daien, C. I., Hua, C., Aletaha, D., Álvaro-Gracia, J. M., Bakkers, M., Brodin, N., Burmester, G. R., Codreanu, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210602 · Cited by 609
An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
Ong, C. K. S., Lirk, P., Tan, C. H., & Seymour, R. A. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.698 · Cited by 587
Smolen, J. S., Landewé, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., Gorter, S., Knevel, R., Nam, J., Schoels, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126532 · Cited by 409
Hodge, J. A., Kawabata, T. T., Krishnaswami, S., Clark, J. D., Telliez, J., Dowty, M. E., Menon, S. S., Lamba, M., & Zwillich, S. H. (2016) · PubMed · Cited by 374
Gaujoux-Viala, C., Smolen, J. S., Landewé, R., Dougados, M., Kvien, T. K., Mola, E. M., Scholte-Voshaar, M., van Riel, P., & Gossec, L. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.127225 · Cited by 360
Tian, H., & Cronstein, B. N. (2007) · PubMed · Cited by 351
Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
Curtis, J. R., & Singh, J. A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.05.044 · Cited by 326
One year in review 2021: pathogenesis of rheumatoid arthritis
Testa, D., Calvacchi, S., Petrelli, F., Giannini, D., Bilia, S., Alunno, A., & Puxeddu, I. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/j1l5l3 · Cited by 314
Zitnay, J. L., Li, Y., Qin, Z., San, B. H., Depalle, B., Reese, S. P., Buehler, M. J., Yu, S. M., & Weiss, J. A. (2017) · Nature Communications · doi:10.1038/ncomms14913 · Cited by 247
Biologic therapy for autoimmune diseases: an update
Rosman, Z., Shoenfeld, Y., & Zandman-Goddard, G. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-88 · Cited by 240
Epidemiology of rheumatic musculoskeletal disorders in the developing world
Chopra, A., & Abdel-Nasser, A. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.07.001 · Cited by 238
Benefits of Exercise in Rheumatoid Arthritis
Cooney, J. K., Law, R.-J., Matschke, V., Lemmey, A. B., Moore, J. P., Ahmad, Y., Jones, J. G., Maddison, P., & Thom, J. M. (2011) · Journal of Aging Research · doi:10.4061/2011/681640 · Cited by 234
State of the art paper Tumor necrosis factor inhibitors – state of knowledge
Lis, K., Kuzawińska, O., & Bałkowiec-Iskra, E. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.47827 · Cited by 186
Rituximab for the treatment of rheumatoid arthritis: an update
Mok, C. C. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s41645 · Cited by 176
Treatment with Biologicals in Rheumatoid Arthritis: An Overview
Rein, P., & Mueller, R. B. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-017-0073-3 · Cited by 174
da Silva, J. C., Mariz, H. A., da Rocha Júnior, L. F., Santana de Oliveira, P. S., Dantas, A. T., Duarte, A. L. B. P., da Rocha Pitta, I., Galdino, S. L., & da Rocha Pitta, M. G. (2013) · Clinics · doi:10.6061/clinics/2013(06)07 · Cited by 172
Pharmacotherapy Options in Rheumatoid Arthritis
Kumar, P., & Banik, S. (2013) · Clinical Medicine Insights Arthritis and Musculoskeletal Disorders · doi:10.4137/cmamd.s5558 · Cited by 125
Immunogenicity and other problems associated with the use of biopharmaceuticals
Tovey, M. G., & Lallemand, C. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611406318 · Cited by 108
Whittle, S., Colebatch, A. N., Buchbinder, R., Edwards, C. J., Adams, K., Englbrecht, M., Hazlewood, G. S., Marks, J. L., Radner, H., Ramiro, S., et al. (2012) · Rheumatology · doi:10.1093/rheumatology/kes032 · Cited by 97
McGonagle, D. G., Hermann, K., & Tan, A. L. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu328 · Cited by 96
Gene expression analysis in RA: towards personalized medicine
Burska, A. N., Roget, K., Blits, M., Gómez, L. S., van de Loo, F., Hazelwood, L. D., Verweij, C. L., Rowe, A., Goulielmos, G. N., van Baarsen, L. G. M., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.48 · Cited by 86
Daïen, C., Hua, C., Combe, B. G., & Landewé, R. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000404 · Cited by 71
Nakamura, S., Suzuki, K., Iijima, H., Hata, Y., Lim, C. R., Ishizawa, Y., Kameda, H., Amano, K., Matsubara, K., Matoba, R., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1052-8 · Cited by 61
Pajarinen, J., Lin, T., Sato, T., Yao, Z., & Goodman, S. B. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb01005a · Cited by 50
Current stage in inflammatory bowel disease: What is next?
Gómez, G. J., Masedo, Á., Yela, C., Martínez-Montiel, M. D. P., & Casís, B. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i40.11282 · Cited by 47
The Efficacy and Safety of Antidepressants in Inflammatory Arthritis: A Cochrane Systematic Review
Richards, B. L., Whittle, S., van der Heijde, D. M. F. M., & Buchbinder, R. (2012) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.120338 · Cited by 42
Cada, D. J., Demaris, K., Levien, T. L., & Baker, D. E. (2013) · Hospital Pharmacy · doi:10.1310/hpj4805-413 · Cited by 41
Rituximab: a review of dermatological applications.
Emer, J. J., & Claire, W. (2009) · PubMed Central · Cited by 37
Biomarkers Predicting a Need for Intensive Treatment in Patients with Early Arthritis
González‐Álvaro, I., Ortiz, A. M., Seoane, I. V., García‐Vicuña, R., Martínez, C., & Gomariz, R. P. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140825123104 · Cited by 35
How Does Leflunomide Modulate the Immune Response in Rheumatoid Arthritis?
Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., & Kirschbaum, B. J. (1999) · BioDrugs · doi:10.2165/00063030-199912040-00007 · Cited by 33
Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
Perpetuo, I. P., Caetano‐Lopes, J., Rodrigues, A. M., Campanilho‐Marques, R., Ponte, C., Canhão, H. M., Ainola, M., & Fonseca, J. E. (2017) · BioMed Research International · doi:10.1155/2017/2690402 · Cited by 30
Anti-TNFα domain antibody construct CEP-37247
Gay, R. D., Clarke, A. W., Elgundi, Z., Domagala, T., Simpson, R. J., Le, N. B., Doyle, A., & Jennings, P. A. (2010) · mAbs · doi:10.4161/mabs.2.6.13493 · Cited by 28
den Broeder, A. A., van Herwaarden, N., & van den Bemt, B. J. F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000487 · Cited by 22
Cited by
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
The Role of M1/M2 Macrophage Polarization in Rheumatoid Arthritis Synovitis
Cutolo, M., Campitiello, R., Gotelli, E., & Soldano, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867260 · Cited by 631
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis
Conforti, A., Di Cola, I., Pavlych, V., Ruscitti, P., Berardicurti, O., Ursini, F., Giacomelli, R., & Cipriani, P. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102735 · Cited by 407
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies
Mueller, A.-L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021) · Cells · doi:10.3390/cells10113017 · Cited by 256
Metadata
- Authors
- Bullock, J., Rizvi, S. A. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., & Ahmed, J.
- Venue
- Medical Principles and Practice
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 27
- Issue
- 6
- Pages
- 501-507
- ISSN
- 1011-7571 (ISSN-L)
- 1423-0151
- OpenAlex
- W2890017737
- Cited by
- 776
- References
- 39
- FWCI
- 19.08
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.